drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (autologous TIL therapy)
drug_description
Autologous tumor-infiltrating lymphocyte (TIL) product expanded ex vivo from a patient’s resected tumor and reinfused to mediate TCR-dependent antitumor cytotoxicity.
nci_thesaurus_concept_id
C205438
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from the patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs BST02 specifically recognize and kill the patients tumor cells.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous TILs expanded ex vivo are reinfused to recognize patient-specific tumor antigens via their native TCRs (MHC-restricted) and exert cytotoxic killing of tumor cells, supported by cytokine release; typically given after lymphodepletion with IL-2 support to enhance engraftment and activity.
drug_name
BST02
nct_id_drug_ref
NCT06173726